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Abstract 
The aim of the present study was to exam-
ine  the  epidemiology,  natural  history,  treat-
ment and long-term survival of patients with
adenosquamous cell carcinoma of the prostate.
The  Surveillance,  Epidemiology,  and  End
Results (SEER) Program database was used to
identify  ASCC  of  prostate  cases  between
January  1973  and  December  2006.  Survival
probabilities were estimated using the Kaplan-
Meier methods and compared using the log-
rank  test.  A  total  of  25  patients  with
adenosquamous cell carcinoma of the prostate
were identified during the study period. The
median  age  was  74  years  (range  53-98).
Twenty  percent  of  study  subjects  presented
with metastatic disease. Among those patients
with known grade (n=16), 75% had poorly or
undifferentiated  histology.  A  total  of  40%  of
study subjects received radical prostatectomy,
while 24% of the patients had primary radia-
tion therapy. The 1-, 3-, and 5-year cancer spe-
cific survival rates for the entire cohort were
55.2%,  37.8%,  and  30.3%,  respectively.  For
patients who underwent prostatectomy, the 1-,
3-, and 5-year survival rates were 78%, 78%,
and 63%, respectively. For the patients who did
not receive prostatectomy, the 1-year survival
rates were 38.7% and none survived to three
years. Adenosquamous cell carcinoma is a rare
aggressive  subtype  of  prostate  cancer  with
poor cancer specific survival. The development
of new therapeutic approaches for this aggres-
sive tumor is urgently needed.  
Introduction 
While adenocarcinoma is the most common
type of carcinoma of the prostate, mixed types
of  carcinoma  of  the  prostate  are  rare.
1,2
Adenosquamous  cell  carcinoma  (ASCC)  is
defined by the presence of both glandular (aci-
nar)  and  squamous  components.  Glandular
and squamous components can be distinct or
can show direct transition. Squamous compo-
nents constitute an average 40% of the tumor,
with a range of 5-95%.
3 Since the first descrip-
tion by Thompson,
4 approximately 20 cases of
ASCC of the prostate have been reported.
3,5-12 Of
all  ASCC  cases  reported  in  literature,  two-
thirds involved patients previously treated for
prostatic  adenocarcinoma  with  hormones
and/or radiation.
3,5-9The remaining one-third of
patients had no history of prostate cancer or
hormonal therapy.
10-13
Little is known of molecular genetic abnor-
malities in this neuplasma. P53 was reported
amulation  in  both  glandular  and  squamous
components.
9 DNA  analysis  on  adenosqua-
mous cancer revealed that the squamous com-
ponent was aneuploid and tetraploid, and the
adenocarcinoma component of the ASCC was
diploid.  The  non-diploid  pattern  predicts  an
aggressive course.
14
There  are  several  theories  to  explain  the
histogenesis  of  ASCC  of  the  prostate:  i)
meteplastic transformation of adenocarcinoma
cells;
15 ii) collision-type tumor;
14,16 iii) ASCC is
derived from pluripotent stem-cells capable of
multidirectional differentiation;
9 iv) for ASCC
occuring after radiation or androgen depriva-
tion  therapy,  a  more  plausible  explanation
would  be  clonal  evolution/divergence  of  per-
sistent carcinoma, secondary to the selective
pressure of therapy.
9
Current literature on ASCC of the prostate
consists predominantly of retrospective reports
or histopathological studies from single insti-
tutional experiences. Available information on
outcomes  of  treatments  is  lacking.  After  an
extensive literature search, only a few cases of
ASCC  with  long-term  follow-up  information
were  found  and  the  majority  of  cases  died
within a year after the diagnosis;
6,12,15,17 so far
no  single  institution  study  has  had  enough
cases to allow a  meaningful analysis of impor-
tant prognostic factors. 
The purpose of this study is to examine nat-
ural history, treatment pattern and long-term
cancer specific survival of patients with pri-
mary ASCC who were identified in the popula-
tion  based  Surveillance,  Epidemiology,  and
End Results (SEER) Program database.  
Materials and Methods 
Data source and study population 
SEER currently consists of 18 statewide and
regional tumor registers spread across the US,
covering approximately 26% of the population.
SEER routinely collects data on patient demo-
graphics (age at diagnosis, gender, race/eth-
nicity and geographical residence at the time
of  diagnosis),  tumor  characteristics  (size,
grade, stage), first course of treatment, as well
as  follow-up  documentation  of  vital  status
(date and cause of death).
18
The  cases  of  ASCC  of  the  prostate  were
extracted  from  the  SEER  on  the  basis  of
anatomic site and histology type. All patients
over the age of 18 years, first diagnosed with
ASCC  between  January  1973  and  December
2006 (n=25), were enrolled in this study.  
SEER summary stage is produced using the
extent  of  disease  information  from  medical
records and pathology reports reviewed at the
time  of  diagnosis.  SEER  general  summary
stage
18 classifies  patients  as  having  local,
regional  (extension  into  adjacent  tissues  or
nodal involvement) or distant disease. Since
the Gleason grading scheme can be used for
the glandular component but not for the squa-
mous component of ASCC, the World Health
Organization’s  standard  grading  system  was
used in this study. “Well, moderately well dif-
ferentiated histology”, and “poorly differentiat-
ed,  undifferentiated  histology”  were  catego-
rized to low- and high-grade, respectively. 
Statistical analysis 
Discrete  data  are  reported  as  frequencies
and compared by c
2 and Fisher’s exact tests as
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appropriate. Continuous data are reported as
mean ± SD and compared by Student’s t-test.
Survival duration was measured by the Kaplan-
Meier method and compared by the log rank
test. Multivariable Cox’s proportional hazards
model was used to identify independent pre-
dictors  of  long-term  cancer  specific  death.
Cases identified at the time of autopsy or by
death certificate only were excluded from the
survival  analyses.  All  statistical  calculations
were  performed  by  SPSS  12.0  (Apache
Software Foundation 2000).  
Results 
Patients’ and tumor characteristics  
Of the 25 patients with ASCC of the prostate
identified  in  the  SEER  database  during  the
study period, the median age at diagnosis was
74 years, with a range of 53 to 98 years. The
majority  of  patients  (84%)  were  Caucassian
while 4 patients belonged to the other ethnic
groups (16%). Twenty percent of patients pre-
sented with metastatic disease. Of 16 patients
whose histology grade information was avail-
able in the SEER database, 12 (75%) had poor-
ly  or  undifferentiated  histology.  Overall,  10
patients (40%) underwent radical prostatecto-
my and 6 patients (24%) received primary radi-
ation therapy. Details of patients’ and tumor
characteristics are shown in Table 1. 
Long-term survival 
The  median  duration  of  follow  up  of  the
entire  cohort  was  11  months  (range  0-95
months); 23 of 25 (92%) patients died during
the follow-up period.  
One patient who was diagnosed at the time
of autopsy was excluded from the cancer spe-
cific  survival  analyses.  A  total  of  24  patents
were  included  in  the  final  survival  analysis.
The  median  cancer  specific  survival  was  16
months (95% CI 0-32) (Figure 1A). There is a
significant difference in cancer specific sur-
vival  rates  between  patients  with  localized/
regional disease and patients with distant dis-
ease (P=0.001) (Figure 1B). In patients with
local/regional disease, there is also a signifi-
cant  cancer  specific  survival  advantage  in
patients who were treated with prostatectomy
compared  to  those  who  were  not  (P=0.02)
(Figure 1C).  
Table 2 presents the 1-, 3- and 5-year cancer
specific  survival  rates  according  to  patients’
and tumor characteristics. The 1-, 3- and 5-
year cancer specific survival rates were 55.2%,
37.8%  and  30.3%,  respectively  (Table  2).
Patients with local disease have a better sur-
vival  rate  than  patients  who  presented  with
advanced disease. The 1-, 3- and 5-year cancer
specific survival rates for patients with local-
Article
Figure 1. (A) Cancer specific survival rate of patients with ASCC of the prostate. (B)
Comparison of cancerspecific survival rates of patients with ASCC of prostate according
to SEER stage. (C) Comparison of cancer specific survival rates according to treatment
in ASCC patients with localized/regional stage only. (RP: radical prostatectomy). 
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ized  stage  were  76.2%,  58.0%  and  46.4%,
respectively.  However,  the  patients  who  pre-
sented with distant disease all died within a
year after diagnosis; the 6-month survival rate
for those patients was only 20%. The median
cancer  specific  survival  for  patients  who
underwent prostatectomy was 65 months (95%
CI 44-86). The 1-, 3- and 5-year cancer specific
survival  rates  were  78.8%,  78.8%  and  63%,
respectively.  For  the  patients  who  did  not
undergo prostatectomy, the 1- and 3-year can-
cer specific survival rates were 38.7% and 0%,
respectively (Table 2). 
Table 3 presents the results of multivariate
survival analyses using Cox’s proportional haz-
ard model in patients with ASCC. After adjust-
ing  for  the  demographic,  clinical  and  treat-
ment related factors, prostatectomy was a sig-
nificant  predictor  of  cancer  specific  survival
(HR 0.1, 95%CI 0.01-1.0).  
Discussion 
Although a single center study reported an
incidence rate of 0.79%,
4 the true incidence of
adenosquamous cell carcinoma (ASCC) of the
prostate is unknown. In this study, we identi-
fied only 25 patients with ASCC of the prostate
in the SEER database during the study period.
The incidence in this population study is much
lower than that reported in the single institu-
tion study.
13 There are several possible expla-
nations for this interesting finding. First of all,
“referral bias” likely exists in single institu-
tion studies which are usually from large, ter-
tiary-care referral centers. The patients with
rare  tumors  are  most  likely  to  visit  referral
centers for a second opinion. In comparison
with  their  community  counterparts,  patholo-
gists from centers of excellence are more like-
ly to have the expertise to indentify this rare
subtype  of  histology.  Second,  there  may  be
“anatomical bias”. Most cases of ASCC of the
prostate were found at the prostatic urethra
and/or adjacent tissues,
13 making them more
readily  accessible  by  transurethral  resection
for bladder tumor (TURP) than by core needle
biopsies. However, TURP was only performed
in patients with symptoms of obstruction. With
the wide use of PSA screening, which usually
leads  to  detection  of  asymptomatic  prostate
cancer by needle biopsy, a squamous compo-
nent in the prostate but not in the needle biop-
sy sample may be missed. Third, practice pat-
tern bias may also have contributed to current
findings.  Two-thirds  of  ASCC  cases  were
reported  to  have  been  found  in  cases  of
prostate  adenocarcinoma  previously  treated
with hormone or radiation therapy.
3,5-9 In cur-
rent clinical practice, a second biopsy is sel-
dom performed in patients with prostate can-
cer; this is because of the perception that the
Article
Table 1. Demographic and clinical characteristics of 25 patients with primary adenosqua-
mous cell carcinoma of prostate. 
Characteristics Group N%
Total 25 100
Age (years) 50-59 28
60-69 7 28
70-79 8 32
≥80 8 32
Ethnicity White 21 84
Others 4 16
Marital status No 5 20
Yes 5 20 80
Grade Low 4 16
High 12 48
Unknown 9 36
SEER Stage Localized/regional 13 52
Distant 5 20
Unknown 7 28
Prostatectomy Yes 10 40
No 15 60
Radiation Yes 6 24
No 19 76
Year of diagnosis 1973-1994 15 60
1995-2006 10 40
Table 2. Median, 1-, 3-, 5- year cancer specific survival of patients with adenosquamous
cell carcinoma of the prostate according to demographic and clinical characteristics.  
Median cancer specific survival Survival (%)
Characteristics months (95%CI) 1-year 3-year 5-year P
All16 (0-32) 55.2 37.8 30.3
SEER Stage
Localized 54 (14-93) 76.2 58.0 46.4 0.001
Distant* 4 (0-8) 00.0 00.0 00.0
Unknown 8 (0-11) 40 00
Prostatectomy
No 7 (3-11) 38.7 00.0 00.0 <0.001
Yes 65 (44-86) 78.8 78.8 63.0
Year
1973-1994 16 (0-64) 55.1 45.9 30.6 0.56
1995-2006 20 (0-56) 56.3 28.1 28.1
*Six months survival rate 20%. CI=confidence interval.
Table  3.  Multivariate  analyses  of  factors  associated  with  cancer  specific  mortality  in
patients with adenosquamous cell carcinoma. 
Characteristics Group Hazard ratio 95% confidence interval P
Age Continuous 0.99 0.93-1.05 0.76
Year of diagnosis 1980-1994 1.00
1995-2004 0.73 0.17-3.20 0.68
SEER stage Local/regional 1.00
Distant 4.36 0.54-35.1 0.17
Unstaged 1.47 0.16-13.4 0.73
Radiation No 1.00
Yes 0.80 0.20-3.24 0.76
Prostatectomy No 1.00
Yes 0.10 0.01-1.0 0.05[Rare Tumors 2010; 2:e47] [page 133]
second biopsy of these patients in the face of
known prostate cancer is not warranted, espe-
cially in the case of advanced stage disease
and elderly patients. Finally, “data source bias”
likely also contributed to the difference in inci-
dence.  SEER  routinely  collects  histological
data at the time of initial diagnosis. Additional
tissue  diagnoses  from  subsequent  biopsies
were not collected; while this information is
readily available in single center retrospective
studies. Some investigators postulate that the
incidence of ASCC and the clinical impact of
this  subtype  is  likely  underestimated  and
underreported.
12 A more accurate estimate of
the true incidence of this subtype of prostate
cancer can only be achieved by tumor banking
and pathological evaluation of additional tis-
sue biopsy specimens from subjects with ade-
nocarcinoma  of  prostate,  including  patients
with hormone refractory disease or those who
received radiation therapy. For example, The
National Cancer Institute Cooperative Prostate
Cancer Tissue Resource (CPCTR) represents
one of the largest sources of pathology-charac-
terized  archival  prostate  cancer  tissue  with
associated  follow-up  data  in  the  world.
19
Similarly  human  frozen  tumor  tissue  banks
with corresponding diagnosis were also estab-
lished in European cancer centers and univer-
sities.
20 Such  infrastructures  would  improve
tissue availability and accessibility to allow the
study of true incidence and the clinical impact
of this rare tumor subtype. 
Since there is no clinical trial specifically
designed for ASCC of the prostate, the optimal
treatment strategy has not been established.
Radical prostatectomy, radiation therapy, hor-
mone or chemotherapy has been used alone or
in combination. In this study, the patients with
local/regional ASCC who received prostatecto-
my had a significant survival benefit compared
to those who did not. Therefore, prostatectomy
should  be  offered  to  those  with  localized
prostate  cancer,  including  healthier  elderly
patients with good performance status. Due to
limited sample size, it is difficult to evaluate
the true impact of radiation on patients’ sur-
vival. Some authors suggested that ASCC of
the prostate responds, at least initially, to hor-
mone  therapy,
10,11 while  others  reported  that
these tumors generally were refractory to hor-
mone  therapy.
13 However,  information  on
response and efficacy of chemotherapy is lack-
ing.  Consistent  with  single  institution  stud-
ies
4,13 patients with ASCC of the prostate usual-
ly present with aggressive disease; 75% of the
patients  with  known  histology  grade  in  our
study had either poorly or undifferentiated his-
tology. The prognosis for patients with ASCC is
very poor and, notably, even in those patients
with  localized  disease  who  subsequently
underwent prostatectomy, suggesting this is a
disease with propensity of early microscopic
dissemination. The 5-year cancer specific sur-
vival rate of 30.3% was significantly lower com-
pared  to  the  99.9%  survival  rate  of  prostate
cancer as a whole.
21 Unfortunately, the outlook
of this disease has not changed in the past
three decades (Table 2). Collectively, the find-
ings from this study and others
1,2 support the
view that ASCC represents a distinct disease
entity.  
Prostate  cancer  is  a  clinically  heteroge-
neous disease, ranging from indolent to rapid
lethal disease, such as in the case of ASCC.
1, 2,21
The observed clinical heterogeneity of prostate
cancer likely reflects the underlying molecular
heterogeneity  among  tumors.  As  our  under-
standing of the genetic basis for prostate can-
cer grows, it is likely that prostate cancer will
be  subdivided  into  ever  more  specific  cate-
gories. Indeed, microarray profiling studies in
prostate cancer have identified clinically rele-
vant  gene-expression  subtypes.
22-24 Further
advancements in molecular biology and pro-
teomics  may  accelerate  this  trend  towards
individual characterization of prostate cancer
and,  ultimately,  personalized  therapy  will  be
tailored to their biological behaviors. Our find-
ing of subtype-related differences in prostate
cancer  has  significant  therapeutic  implica-
tions: better therapy of prostate cancer is more
likely to be achieved by investigating each sub-
type of prostate cancer separately rather than
grouping them all together.
20 Research on the
rare subtype of prostate cancer may also have
important ramifications for general oncologi-
cal practice. For example, clear cell carcinoma
is a subtype of kidney tumor. Characterization
of the role of the VHL gene in oncogenesis of
clear cell carcinoma
25 led to the development of
antiangiogenesis therapy in the treatment of
renal cell carcinoma.
26 The utility of tyrosine
kinase inhibitors is now being defined in a
wide  variety  of  both  rare  and  common  neo-
plasms.
27
There are several limitations to this study.
First, the information regarding receipt of hor-
mone or chemotherapy and patients’ co-mor-
bidities is not available in the SEER database,
all of which may influence survival in cancer
patients. However, the analysis reported here
attempted to overcome this data limitation by
measuring  prostate  cancer  specific  survival,
rather than overall survival. The results from
this study should be interpreted with caution
since the sample size used may still not be big
enough to fully describe the factors that affect
the incidence, treatment choice, and survival
of this rare prostate cancer subtype.  
Conclusions 
Adenosquamous  cell  carcinoma  is  a  rare
aggressive subtype of prostate cancer with a
poor outcome. Further study to understand the
molecular mechanism underlining the biologi-
cal behavior of ASCC is planned. The develop-
ment of new therapeutic approaches for this
aggressive tumor is urgently needed.  
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